Released: May 13, 2020

Defense Health Program
Department of Defense Duchenne Muscular Dystrophy Research Program
Anticipated Funding Opportunities for Fiscal Year 2020 (FY20)

The FY20 Defense Appropriations Act provides funding to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support research addressing discovery and development of therapeutics, devices, and other interventions. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications for submission to the anticipated FY20 DMDRP Program Announcements. This pre-announcement should not be construed as an obligation by the government. The FY20 DMDRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the website. Pre-application and application deadlines will be available when the Program Announcements are released. 

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Development Award Independent investigators at all academic levels (or equivalent).
  • Supports the development of innovative, high-impact ideas that advance the understanding of Duchenne muscular dystrophy (DMD) and ultimately lead to improved outcomes.
  • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged.
  • Preliminary data required.
  • Clinical trials are not allowed.
  • Maximum funding of $350,000 in total costs.
  • Maximum period of performance is years.
Translational Research Partnership Award Investigators at or above the level of Assistant Professor (or equivalent).
  • Supports the development of translational research collaborations between two independent investigators to address a critical problem or question in DMD and to accelerate the movement of promising ideas into clinical application.
  • Partnerships where one partner in the collaboration is a research scientist and the other is a clinician are strongly encouraged.
  • Must address one of the FY20 Translational Research Partnership Award Focus Areas
  • Preliminary data required.
  • Clinical trials are allowed.
  • Maximum combined funding of $1,200,000 for direct costs (plus indirect costs).
  • Maximum period of performance is years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022